Scientific Program| Cancer Conferences | Oncology Conferences |Global cancer 2019 | Japan | Asia Pacific | USA | Europe | Middle East

Conference Series Ltd invites all the participants across the globe to attend 3^rd Global Summit on Oncology & Cancer Tokyo, Japan.

Submit your Abstract

or e-mail to

globalcancer@cancermeet.org
globalcancer@conferencesseries.org
asiaevents@conferenceseries.com

Day 1 : May 6, 2019

Keynote Forum

Thomas W Kozlowski

Principal Consultant, JCI, Singapore

Keynote: Communicating clearly and effectively to patients

Time : 09:30-10:10

Conference Series Global Cancer 2019 International Conference Keynote Speaker Thomas W Kozlowski photo

Biography:

Thomas Kozlowski has over 35 years of experience in health care, he is a Chief Executive Officer of a 13-site state operation for a private ambulatory health care agency and leader in a variety of not-for-profit and investor-owned health care delivery organizations. Thomas Kozlowski has over 15 years of experience at The Joint Commission and 18 years at Joint Commission International, Thomas Kozlowski joined Joint Commission Resources in 2001 and subsequently consulted with both domestic and international health care organizations in the areas of accreditation readiness and standards compliance. Dr. Kozlowski's consulting expertise in hospital, ambulatory care, behavioral health care, and long term care settings includes operational assessment, patient safety assessment, environment of care, executive leadership and governing bodies, performance improvement, implementation strategies for rapid response teams, electronic health record assessment, and incorporating tracer methodology and the periodic performance review as management tools.

Abstract:

In today’s very, complex healthcare environment where a patient will easily interact with multiple care givers during their course of care/treatment and delivery. The key common issue for any harm or potential injury to the patient is Poor or Lack of CLEAR Communication. This presentation will review some simple ways to improve communication between the care giver and the patient/family, review the risks or outcome of care resulting from unclear communication and highlight some global solutions toward achieving a better improved communication plan between the patient and the provider. JCI standard references will be incorporated as potential tools or possible requirements to be adopted by an organization as a guide for clearer forms of communication. Discussion during the presentation will highlight the one area during care where a clear level of communication and listening from both the patient and the care giver is crucial – that being at the point of DISCHARGE. This is such an important step in the delivery of continuity of care but is often done very quickly and with very little follow up on the understanding of the discharge planning recommended. There will be a review of the types of Channels of Communication (either Verbal or Written) which is seemed to give the best outcome and when it is appropriate to utilize a certain channel of communication. The presentation will highlight the common causes of failures and demonstrate some of such failures which occur on a day to day basis globally with the use of JCI “International Patient Safety Goals” which could affect the course of care for the cancer patient during their treatment. There will be reference to a “white paper” which addressed the common issues of potential harm due to lack of clear and simple communications. These findings from the white paper will be linked to how one can identify the common barriers within an organization that fosters the lack of good communication. In addition, to the identification of the barriers, there will be time spend on review of the impact and challenges which will result in poor communication such as longer length of stay – increased medication errors – potential infections due to lack of understanding on basic prevention techniques – lack of required follow-up care, these are just a few of the potential impacts/challenges that are possible unsafe and non-quality outcomes resulting in RISK to the patient. Focus will be on medical orders and critical test results – cultural barriers – language issues – aging patient population – and how the international JCI standards could be use as a tool for monitoring the level of communication between the care giver and the patient to achieve a ZERO HARM outcome of care.

Keynote Forum

Vinay Sharma

University of the Witwatersrand-Johannesburg, South Africa

Keynote: How will MRI impact on future of radiation oncology?

Time : 10:10-10:50

Conference Series Global Cancer 2019 International Conference Keynote Speaker Vinay Sharma photo

Biography:

Vinay Sharma is currently working as Head of Department of Radiation Oncology at Charlotte Maxeke Johannesburg Academic Hospital, University of Witwatersrand. He has published over 150 papers in in national and international peer reviewed journals as well as book chapters. His main research interest is in breast cancers as well as gynecological malignancies.

Abstract:

State of art radiotherapy has ability to deliver highly conformal doses of radiation that can target large tumors and avoid normal tissues with high precision; however, the limitations of conventional online imaging hinder this technology from achieving its true potential. Advances in MR imaging allow non-invasive assessment of morphological, biological and functional process in tissue and therefore, may provide tools for early assessment and prediction of tumors and normal tissue responses to irradiation. Imaging and pathological information combined from a larger patient cohort can be used to develop a predictive model. Superior soft tissue visualization combined with the MR Guided Radiation Therapy (MRgRT) ability to dynamically adjust the treatment plan and or gate the treatment delivery to account for inter/intra-fractional anatomical changes offers great promise to further enhance treatment precision for abdominal and thoracic anatomical sites. Tumors are not uniform within a volume, which may be responsible for the variable outcomes from the same therapy among patients. Tumors heterogeneity sub regions (habitats) shown by spatial distributions of MR images define distinct physiologies such as viable cells, necrosis and oedema and could provide information for therapeutic decision support. Advances in MRI can also assist in obtaining images that reflects underlying pathophysiology and that these relationships can be revealed via. quantitative image analyses.

Keynote Forum

Joshua K S Ko

Hong Kong Baptist University, China

Keynote: From cytotoxic tumor-targeting to regulation of the tumor microenvironment: New considerations in pancreatic cancer chemotherapy

Time : 10:50-11:30

Conference Series Global Cancer 2019 International Conference Keynote Speaker Joshua K S Ko photo

Biography:

Joshua K S Ko has completed his PhD in Pharmacology at the University of Hong Kong Medical School after completion of his undergraduate training at the University of Toronto, Canada with double specialists in Toxicology and Nutritional Sciences. He has been actively involved in many research projects, published over 100 papers in reputed journals. He is currently working as an Editorial Board Member of various journals including those of the Nature Publishing Group and also Member of the American Association for Cancer Research (AACR), European Association for Cancer Research (EACR) and International Union of Basic and Clinical Pharmacology (IUPHAR).

Abstract:

Current drug treatments for pancreatic cancer fail to effectively prolong survival and are often limited by dose-related toxicity in patients. Traditional school of chemotherapy focuses upon eradication of tumor cells, causing systemic side effects due to collateral damage in non-malignant normal cells of the host. Contemporary chemotherapeutic approach also considers the Tumor-Micro Environment (TME) when choosing new molecular targets, aiming to impede tumor progression by maintaining optimal tumor-microenvironment interactions. TME comprises tumor cells, endothelial cells, TumorAssociated Macrophages (TAM), inflammatory and immune cells, as well as stromal factors such as Extracellular Matrix (ECM). Experimental data have demonstrated the role of these individual components in promoting tumor growth and progression. During epithelial-mesenchymal transition, cell-ECM interactions would reorganize the cytoskeleton to increase the migratory activity and invasiveness of cells, facilitating tumor progression and metastasis. Besides, macrophages in tumor inflammatory microenvironment could release vasoactive mediators like VEGF and chemokines that together promote tumor angiogenesis. In addition, tumor immunity could also be triggered due to anti-tumoral T cell responses that kill tumor cells by the CD8 cytotoxic T-lymphocyte recognizing major histocompatibility complex class I restricted antigens expressed on the surface of tumor cells. Here, the tumor-targeting ability of test drugs with the potential to induce tumor immunity reprogramming will be illustrated. Taken together, effective control of the tumor microenvironment may open up a brand new field for contemporary anti-tumor chemotherapy. Discovery of novel agents that possess target-specific anti-tumorigenic potential through distinctive mechanism while concomitantly modulating the tumor microenvironment would largely provoke pancreatic cancer chemotherapy efficacy.

Keynote Forum

Salam Azad

Soheli Mirza Cancer Foundation

Keynote: Awareness About Cancer

Time : 11:50-12:30

Conference Series Global Cancer 2019 International Conference Keynote Speaker Salam Azad photo

Biography:

Salam Azad is a freelance Writer and President of Soheli Mirza Cancer Foundation. Azad had raised the issue of Islamist fundamentalism. Madrasa (Islamic School) education and the practice of issuing fatwa. A fearless writer, continues to crusade against injustice committed by Bangladesh society and government, particularly the failure to protect the rights of the minorities.

Abstract:

What is the cause of cancer? Genetic, food habit, smoking etc? Nobody knows actual cause of Cancer. If know, medicine for cure of Cancer invented and thousand of man-women-children can able to survive. Suspected some of cause, like smoking. If the cause of lunch cancer of smoking. Why not stop from all over the world cultivation of tobacco? Awareness better than treatment. If a person is well aware about cancer, her / his malignancy diseased can detect early or earliest. Early detection means extending her / his life. Before operation or starting the treatment protocol it is mandatory to find the stage of malignancy. If stage crosses two please don’t go to operation or don’t give the patients any kind of treatment protocol. Because sometimes Chemotherapy more harmful, than cancer. Chemotherapy kills immunity of human body, Chemotherapy kill or reduce WBC etc. We know post operation Cancer cell are increasing multiply method. I repeated before operation it is mandatory that diagnosis the stage of malignancy. If Cancer patients cross the stage two please don’t go to operation or apply on his/her this kind of costly treatment. You simply ask what she / he like and love. If patients love to religion practices, please allow. If patients feel singing song or lessening song, please allow. If Cancer patients interested to read or write, please allow. If Cancer patients interested to love birds, trees, blue sky, moon, rain or any others natural beauty, please allow. That is the treatment of his / her, which one he / she love or like. Cancer patients able to pass peaceful few time, few month or few year. Without torture of operation, torture of treatment protocol, like Chemo therapy, Radio therapy, Immunotherapy etc. I heartily recommend about recherché. Recherché can find out proper way, only recherché can invent that medicine; which one cures Cancer. I submit humble request to leading country and prominent organization all over the World, please give more and more allocation and donation for invent Medicine for the cancer cure.

Radiation Oncology | Cancer & Stem Cell Therapy | Surgical Oncology | Cancer Immunotherapy | Cancer Cell Biology and Genetics

Location: Meeting Room 1

Chair

Thomas W Kozlowski

Asia Pacific Regional Office Singapore, Singapore

Session Introduction

Kunal Sharma

SRL Diagnostics, India

Title: Paradigm shift towards molecular basis of cancer diagnosis and treatment- The hematolymphoid perspective

Time : 12:30-13:00

Biography:

Kunal Sharma is currently working as a Consultant Oncopathologist, Molecular Pathologist & Section Head with SRL Diagnostics, India. He was in past working as Consultant Oncopathologist & Head of Quality Assurance at CORE Diagnostics Pvt. Ltd. He has been a guest faculty & presenter at numerous international and national conferences like Lymphoma & Myeloma Congress- New York, CAP-Chicago, The International Society of Paediatric Oncology (SIOP), Nigerian Medical Association, Dhaka Medical College & Bangladesh association of Hematologists, Indian Cancer Congress, ISMPOCON, YROC, ONCOCON etc. He was the faculty & mentor of the largest National hands on IHC workshop (D-I-Y) at JNMC, Belgavi. He has numerous international publications including first reported case of Cellular Ovarian Fibroma in India. He completed his MBBS with aggregate of 73% and received his Post-graduate training (DNB) in Oncopathology from HCG Cancer Hospital, Bangalore.

Abstract:

Diagnosis of diseases especially neoplasms has witnessed a monumental change in its approach. Up until a few years back, the focus lied on histomorphological diagnosis and a blanket treatment was administered based on the disease. With careful understanding of difference in clinical course and treatment response in different patients suffering from the same disease, there arose a need to understand tumor biology to prognosticate and individualize treatment. Research on genetic basis of various neoplasms highlighted different tumor biology and actionable mutation targets in the same disease thus giving rise to the need for detecting these mutations and development of antibodies/molecules which can target them. Hematolymphoid malignancies were one of the earliest to be decoded for different tumor biology, prognosis, response to conventional treatment and need for different treatment strategies based on the underlying genetic mutation. We look into the paradigm shift in the diagnosis of these neoplasms, how the approach has progressively changed from diagnosis based on morphology to present times, classifying prognosis and personalizing treatment, based on the underlying genetic biology.

Baljeet Singh Talwar

Fight Cancer Global, India

Title: Application of microwave thermometry in early detection of Breast Cancer

Time : 14:00-14:30

Biography:

Baljeet Singh Talwar is a graduate from Moscow Power Engineering Institute (Technical University) with a passion of Microwave Technology and has a vast experience in International Business in healthcare(Pharmaceutical & Information Technology).He has the experience of handling scientific and technical development, management of research, interaction with medical consultants of the project. Organization of R & D, production of medical equipment, international scientific cooperation & publications.

Abstract:

Cancer mortality can be reduced if cases are detected and treated early. The lack of awareness, suboptimal medical infrastructure; less availability of screening and low doctor-patient ratio are the prime reasons for the scary statistics of increase in breast cancer load. Microwave Thermometry (MT) is used in risk estimation, the diagnosis of breast pathology and in assessing the effect of neo-adjuvant therapy for breast cancer treatment. It allows the evaluation of thermal changes both at the skin surface and inside the breast tissue. The device facilitates passive, painless, radiation-free and entirely noninvasive diagnostic procedures to pinpoint the changes in temperature that invariably precede structural changes in tissue. The temperature of a malignant tumor is a universal indicator of the growth rate of the tumor. Tumor temperature can be used as a prediction of the benefit of individual therapies and in monitoring the efficacy of breast cancer treatment. The device provides additional information about the severity of proliferative processes, manifested by thermal activity. This is the only device on a decentralized platform suitable for mass screening programs which will bring the Paradigm shift from reactive breast cancer care to care that is predictive, preventive, personalized and participatory.

Daniel Gandia

National University of Buenos Aires, Argentina

Title: The old and the new in medical Cancer therapy

Time : 14:30-15:00

Biography:

Daniel Gandia is a currently working as a Clinical Oncologist who has been involved in Cancer Medicine for many years and also in the guidance of clinical oncology trials in an important worldwide American CRO. He has published several papers in important journals and he also teaches Cellular and Molecular Biology at the School of Medicine in Buenos Aires.

Abstract:

Medical cancer treatment has evolved in a geometric manner since Gilman´s Mechlorethamine introduction into the bedside. Chemotherapy was born and rapidly proved its worth in different tumors and different clinical settings. Initially the bright results were seen in hematologic malignancies, namely complete remissions in some types of leukemias and lymphomas and posteriorly in solid tumors it changed the natural disease history in osteosarcoma, becoming adjuvant methotrexate the new overall survival drug in this malignancy. Many pediatric and young adults’ tumors comported complete remissions with chemotherapy, rendering them as curable diseases. As this, testicular cancer became the first example of a curable cancer model within advanced solid tumors (Cisplatin was the gladiator here). Even when the first clinical trial became from the sixties, during the seventies Oncologists became interested in the after surgery chemo in breast cancer. Two pivotal trials (US and Europe), continue showing that even nearly 40 years after, the overall survival benefit of adjuvant chemo in this disease is impressive. As many as with chemo, hormonotherapy proved and continue to prove its worth in postmenopausal breast cancer women. Adding to the before, two milestones in chemo history are the role of chemo in larynx organ preservation and its positive role in the colorectal cancer adjuvant setting. Taking as a profit chemo radio sensitizer power, the role of concomitant chemotherapy and radiotherapy came up to age: Head neck, rectal cancer, anal cancer only to mention some tumor topographies amenable to this combined approach with organ preservation objectives. As time passed, new techniques in molecular imaging created new magic little bullets named them small molecules and leading this to the creation of the target or directed cancer therapy. The druggable targets here are inner cellular membrane and cytosolic proteins, mainly tyrosine kinases and mutant DNA segments and/or mutant oncogenes. As some tumors to be treated with them, were historically chemo-insensible, the real benefit in renal cancer and melanoma became notorious. Tumor metastatic shrinkage became a reality in these before-mentioned malignancies. César Milstein Nature 1975 Letter (discovery of the Monoclonal Antibodies) was the road to the beautiful landscape that is Immune Oncology today. We treat patients with vaccine, leading this to impressive clinical results in melanoma, lung, kidney, lymphomas and so on. Cellular Immunology is weakened in cancer but there are some molecules that block T Lymphocytes surface, so they couldn’t go to the tumor target to eat them. This novel type of treatment, de-block the lazy lymphocytes. In the road of Immunology there are other-related-immune-novel compounds in trials and also new vaccines. In the future and not so far, we will cure still difficult-to-treat types of advanced cancer. Currently we have some tumor tissue complaints such as tumor heterogeneity that leads to cellular and clinical tumor resistance. Genomics and Proteomics are helping us with this and are currently at the bedside. In the meantime, at the bench side is Gene therapy. Cancer is mainly a DNA-disease and targeting what is correct can show us the long and winding road to a definite cure of this still deadly disease.

Prissadee Thanaphongdecha

Khonkaen University, Thailand

Title: Infection with CagA+ Helicobacter pylori induces epithelial to mesenchymal transition in human cholangiocytes

Time : 15:20-15:50

Biography:

Prissadee Thanaphongdecha has done Doctoral of philosophy in Pathobiology and Bachelor degree in Medical science. He is currently working in Faculty of medicine, Khonkaen university, Thailand

Abstract:

Recent reports suggest that the East Asian liver fluke Opisthorchis viverrini serves as a reservoir of Helicobacter pylori, which is implicated in pathogenesis of Opisthorchiasis-associated cholangiocarcinoma(CCA). The affected cholangiocyte lining intrahepatic biliary tract might be the origin of CCA. Here we investigated interaction of CagA+ve Helicobacter pylori and Helicobacter bilis with H69 cells, an immortalized form of human cholangiocyte. Exposure of H69 cells to increasing numbers of H. pylori at 0, 1, 10,100 bacteria per H69 cell for 24 hours induced morphological changes in cholangiocytes including the appearance of mesenchymal phenotype, profusion of thread-like filopodia and loss of cell-cell contact, in dose-dependent fashion. In parallel, changes in mRNA expression followed exposure to H. pylori, with increased expression of Epithelial to Mesenchymal Transition (EMT) associated-factors including snail, slug, vimentin, matrix metalloprotease, zinc finger E-boxbinding homeobox, and cancer stem cell marker CD44. Transcription levels encoding cell adhesion marker CD24 decreased. Analysis in real time using the xCELLigence approach revealed that exposure to 10 to 50 of H. pylori stimulated migration of H69 cells and CCLP1 cells, a derived form of human cholangiocarcinoma, and invasion through Matrigel extracellular matrix. Similarly, 10 bacteria of CagA+ve H. pylori but not H. bilis stimulated contact-independent colony establishment in soft agar. These findings support the hypothesis that infection with H. pylori contributes to the fibrogenesis and malignant transformation of the biliary epithelium.

Saeed Soroush

Guilan University School of Medicine, Iran

Title: Study of epigenomic changes (noncoding -tag.oncogene) in primary cells of cancer patients than biopsy cells from normal tissue

Time : 15:50-16:20

Biography:

Saeed Soroush began his education in 2013 in medicine in Gilan University of Medical Sciences, Rasht-IRAN. He has published more than 10 papers in reputed journals and has been serving as an editorial board member of repute.

Abstract:

The epigenetic is a set of controlled reversible processes which causes inherited changes in the expression of genes Independent of the change in the nucleotide sequence of DNA. Changes in heterochromatin to yochromatin and vice versa. In DNA Methylation, Histone Modifications are considered as epigenetic mechanisms which regulates target genes in the transcription machine and On the other hand, the interaction of non-coding RNAs like Micro RNAs With target gene has identified their roles in the growth of differentiation and cell death. Therefore, epigenetic factors directly or indirectly change the expression of Micro RNAs in the cell. Certainly failure in these mechanisms leads to activating or inhibiting different messaging pathways and causing diseases such as cancer. As you know, the differentiation and survival of cells occur due to constant gene control patterns that also cancer is created as a result of a change in expression of the activity of carcinogenic genes or tumor suppressor genes. The expression of genes at the DNA and chromatin levels is regulated through epigenetic mechanisms. Of these, some small molecules and drugs that interact with specific sequences of DNA can be modified locally and allow the transcriptional machine to reach the target genes and, ultimately, to change the heterochromatin to the cochromatin,can be mentioned.

The epigenomic settings are considered in four ways:

1. Adjustment at the level of chromatin structure

2. Adjustment on the surface of Micro RNAs

3. Adjustment at the level of the histone structure

4. Adjustment at the level of DNA methylation

This hypothesis can be considered that in each replication of the somatic cells, the length of the telomeres is reduced, but in the cancer cells, the telomere length is fixed due to the telomerase activity and as drug compounds connect to the above structures valuable route in inhibiting telomeres and thus stopping the proliferation of cancer cells.

Mehrnaz Ajorloo

Shahid Beheshti University of Medical Sciences, Iran

Title: The role of genetic factors in the treatment and prognosis of cancer

Time : 16:20-16:50

Biography:

Mehrnaz Ajorloo is a Biotechnologist, and done her education from Shahid Beheshti University of Medical. She has published more than 10 papers in reputed journals and has been serving as an editorial board member of repute.

Abstract:

Generally, cancer is caused by uncontrolled cell division due to the interference of environmental factors and genetic disorders. Among of the key genes involved in the guidance of cancer cells can be mentioned to Oncogenes, tumor suppressor genes, restorative genes and responsible for planned death. In recent pathologic studies that tumor size was calculated based on millimeters, Percentage of tubular body, mitosis and polymorphisms rates express that there is a direct correlation between tumor size and tissue grading with genetic factors. In this regard, some factors such as tumor size, tumor stage, type, estrogen and progesterone receptor status, P53 and HER2 have a more effective role in the prognosis of cancer. For example, the restorer gene BRCA-1 located on the chromosome 17q21 can produce proteins that have the power to correct defective genes. This protein contains Zink Finger, which in addition to controlling the expression of related genes, also has the ability to repair fractures of double strands of DNA. As a result, all genes in the cells naturally get damage by natural and metabolic factors that require restorative proteins. For this reason, prognosis that can be examined with genetic markers, in relation to the normal cells that go out of their standard pathway and become cancerous, it can be very helpful in the diagnosis process .